Brief: EQL Pharma Posts Revised Offer for Sensidose
24/04/2023 08:23
Apr 24 (Reuters) - EQL Pharma AB announces a revised unconditioned cash offer of SEK 8.40 per share to the shareholders of Sensidose Aktiebolag. * Shareholders of Sensidose are offered SEK 8.40 in cash per share in Sensidose * Revised Offer exceeds the offer of SEK 8 per share published by Navamedic ASA on 22 April 2023 by SEK 0.40 per share